Medical therapy for crohn's disease: The state of the art

Surgical Clinics of North America

Volumn 81, Issue 1, 2001, Pages 71-101

  Stein, Robert B ^a,b   Lichtenstein, Gary R ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIMYCOBACTERIAL AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; RECOMBINANT INTERLEUKIN 10; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ANUS FISTULA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENETIC ENGINEERING; HEADACHE; HUMAN; HYPERTENSION; IMMUNOMODULATION; NEPHROTOXICITY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; TOTAL PARENTERAL NUTRITION; TREATMENT PLANNING;

EID: 0035135776     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70274-7     Document Type: Article

References (170)

1. The clinical effect of salazosulfapyridine (salazopyrin) in Crohn's disease
2. A controlled double-blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission
3. Malignancies in rheumatoid arthritis patients treated with cyclosporin A
4. Methotrexate in Crohn's disease: Results of a double-blind, randomized, placebo-controlled trial
5. An experiment to determine the active therapeutic moiety of sulfasalazine
6. Safety and activity evaluation of rh-IL-11 in subjects with active Crohn's disease
7. Budesonide versus prednisone in the treatment of active Crohn's disease
8. Sulfasalazine and salicylazosulfadimidine in ulcerative colitis
9. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease
10. A new enteric coated preparation of omega-3 fatty acids for preventing post-surgical recurrence in Crohn's disease
11. Healing of perineal Crohn's disease with metronidazole
12. Usefulness of azathioprine to maintain cyclosporine induced remission in severe steroid refractory inflammatory bowel disease
13. The treatment of severe chronically active Crohn's disease by T8 suppressor cell lyphapheresis
14. The relationship between infliximab treatment and lymphoma in Crohn's disease
15. Group atD-A: Mesalazine (Pentasa) prophylaxis in Crohn's disease: A multicenter controlled trial
16. Long term follow-up of patients with Crohn's disease treated with azathioprine or 6 mercaptopurine
17. Metronidazole therapy for perineal Crohn's disease: A follow-up study
18. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies
19. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: Is it useful? Our four-year experience
20. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease
21. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease
22. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease
23. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
24. Oral budesonide is as effective as oral predrdsolone in active Crohn's disease
25. A controlled double-blind study of azathioprine in the management of Crohn's disease
26. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease
27. The risk of neoplasms in patients treated with cyclosporin A
28. Infliximab in Crohn's disease: First anniversary clinical experience
29. Intravenous cyclosporin in ulcerative colitis: A five-year experience
30. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)
31. The role of leukoperda in the 6-mercaptopurine induced remission of refractory Crohn's disease
32. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience
33. Azathioprine metabollte levels predict clinical responsiveness to therapy in IBD
34. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
35. Controlled trial of oral 5-aminosalicylic acid for prevention of early relapses in Crohn's disease
36. Postoperative recurrence of Crohn's disease: Pathophysiology and prevention
37. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
38. Duration of response following cessation of infliximab therapy for active or fistulizing Crohn's disease
39. Controlled trial of sulfasalazine in the treatment of ulcerative colitis
40. Optimizing and individualizing 6-MP therapy in IBD: The role of 6-MP metabolite levels and TPMT genotyping
41. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyc̈losporine
42. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
43. Potential mediators on inflammatory bowel disease
44. Review article: The medical management of Crohn's disease
45. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial. German Budesonide Study Group
46. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A multicenter trial
47. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
48. Clinical experience with infliximab therapy in 100 Crohn's disease patients
49. Low-dose cyclosporine for the treatment of Crohn's disease
50. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
51. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators
52. A randomized, double-blind, placebo-controlled, multicenter trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
53. Steroid-unresponsive acute attacks of inflammatory bowel disease: Immtmomodulation by tacrolimus (FK506)
54. Oral budesonide as maintenance therapy in Crohn's disease: Results of a 12-month study. Global Budesonide Study Group
55. Prevention of Crohn's disease recurrences after intestinal resection with Eudragit-L coated 5-aminosalicylic acid: Preliminary results of a one year placebo-controlled study
56. Mycophenolate mofetil in patients with Crohn's disease
57. Inflammatory bowel disease: Etiology and pathogenesis
58. Placebo-controlled trial of Claversal in the prevention of early relapse after "curative" resection for Crohn's disease
59. Impared folic acid absorption in inflammatory bowel disease: Effects of salicylazosulfapyridine (Azulfidine)
60. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study (GETAID)
61. Clinical tolerance to three 5-ASA releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulfasalazine
62. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisone
63. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group
64. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group
65. Combination ciprofloxacin and metronidazole for active Crohn's disease
66. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease
67. Low-dose oral pH-modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group
68. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission in inactive Crohn's disease
69. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease
70. Results of quadruple antimycobacterial chemotherapy in 17 Crohn's disease patients completing six months of treatment
71. Inflammatory bowel disease
72. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease
73. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment
74. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A
75. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease
76. Immunosuppressive drugs in inflammatory bowel disease: A review of their mechanisms of efficacy and place in therapy
77. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group
78. Metronidazole therapy for Crohn's disease and associated fistulae
79. Oral cyclosporine for chronic active Crohn's disease: A multicentre controlled trial
80. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease
81. Treatment of Crohn's disease with azathioprine: A controlled evaluation
82. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease
83. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trial
84. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease
85. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine
86. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease
87. Cyclosporin for severe ulcerative colitis: A user's guide
88. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
89. Hyperbaric oxygen for perianal Crohn's disease
90. Sulfasalazine in asymptomatic Crohn's disease: A multicenter trial
91. Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
92. The future has arrived: Biologic therapy for Crohn's disease
93. Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease
94. Treatment of fistulizing Crohn's disease
95. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI
96. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment of Crohn's disease perianal fistulae
97. The place for methotrexate in the treatment of refractory Crohn's disease
98. Slow-release 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn's disease
99. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
100. Parenteral nutrition in inflammatory bowel disease
101. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease
102. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis
103. Comparison of elemental and peptide-based diets in the treatment of acute Crohn's disease
104. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
105. Sulfasalazine intolerance: A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease
106. Double-blind withdrawal trial of azathioprine as maintenance treatment in Crohn's disease
107. Consistent treatment benefit with infliximab in patients with fistulizing Crohn's disease
108. Neoral may be as effective as intravenous cyclosporine in the treatment of steroid-resistant ulcerative colitis
109. Methotrexate in chronic active Crohn's disease: A double-blind, randomized, Israeli multicenter trial
110. Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis
111. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
112. Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regimen
113. Metronidazole plus ciprofloxacin in the treatment of active refractory Crohn's disease
114. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
115. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study
116. Efficacy of cyclosporine in treatment of fistula of Crohn's disease
117. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long term toxicity
118. Infliximab for the treatment of fistulas in patients with Crohn's disease
119. Effects of olsalazine and sulfasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects
120. 5-Aminosalicylic acid in the treatment of Crohn's disease: A 16-week double-blind, placebo-controlled, multicentre study with Pentasa
121. Controlled trial of azathioprine in Crohn's disease
122. A controlled trial of azathioprine in Crohn's disease
123. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
124. A comparison of budesonide with prednisolone for active Crohn's disease
125. A placebo-controlled trial of metronidazole for recurrence prevention of Crohn's disease after resection of the terminal ileum
126. Rifabutin therapy in patients with recurrent Crohn's disease after ileocolonic resection
127. Nitroimidazole antibiotics are efficacious for prophylaxis of postoperative recurrence of Crohn's disease: A placebo-controlled trial
128. A critical review of cyclosporine therapy in inflammatory bowel disease
129. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
130. A randomized controlled trial of CDP571, a humanized antibody to TNF-α in moderately to severely active Crohn's disease
131. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group
132. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn's disease
133. A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease
134. The mechanism of action of cyclosporin A and FK-506
135. Anti-sense ICAM-1 (1515-2302) for subcutaneous treatment of chronic active Crohn's disease (CACD): Lack of efficacy in a prospective, double-blind, multicenter trial
136. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease
137. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Pentasa Crohn's Disease Study Group
138. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease
139. Randomized controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease
140. European trial of cyclosporin in chronic active Crohn's disease: A 12-month study
141. Complications during cyclosporine therapy for inflammatory bowel disease
142. Medical therapy for inflammatory bowel disease
143. Sulfasalazine and mesalamine for the maintenance treatment of Crohn's disease: A meta-analysis
144. Toxicity associated with the use of cyclosporine in patients with inflammatory bowel disease
145. Newer treatments for inflammatory bowel disease
146. Phase I multiple-dose pilot study of chimeric monoclonal M-T412 (anti-CD4) antibodies in Crohn's disease
147. National Cooperative Crohn's disease study (NCCDS): Results of drug treatment
148. Double-blind, placebo-controlled trial of metronidazole in Crohn's disease
149. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group
150. Sulfasalazine: II. Some notes on the discovery and development of Salazopyrin
151. Sulfasalazine: Adverse effects and desensitization
152. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
153. Is long-term methotrexate (MTX) use hepatotoxic in inflammatory bowel disease patients?
154. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group
155. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease
156. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of syptomatic Crohn's colitis and ileocolitis
157. Cortisone in ulcerative colitis: Final report on a therapeutic trial
158. Long-term treatment of perianal fistulous Crohn's disease with ciprofloxacin
159. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden: II. Result
160. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease
161. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
162. Effect of sulfasalazine in patients with active Crohn's disease: A controlled, double-blind study
163. Consistency of treatment benefit with infliximab in patients with moderate to severe active Crohn's disease
164. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
165. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
166. New oral preparations for maintenance therapy of Crohn's disease
167. The long-term prophylactic effect of salazosulfapyridine (salazopyrin) in primarily resected patients with Crohn's disease: A controlled double-blind trial
168. Controlled trial of azathioprine in Crohn's disease
169. Ciprofloxacin may be useful in Crohn's disease
170. A placebo-controlled trial of ICAM-1 antisense ollgonucleotide in the treatment of Crohn's disease